TXG 10x Genomics: Earnings growth forecast for next year
10x Genomics, Inc. (TXG) generates revenue through the sale of cell analysis systems and high-margin reagents, driving impressive growth. The profit growth rate model for the coming year visualizes these expectations, where the latest parameter is -7.20. However, success relies on research center grants, while business sustainability is guaranteed by a robust patent shield in the field of spatial biology.
TXG (10x Genomics Inc): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- company stock capitalization data:
- book capitalization indicators:
- company liabilities and liquidity data:
Total Debt to Capital 10x Genomics, Inc.|TXG - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity 10x Genomics, Inc.|TXG - Company Aggregate Debt|Debts to Book Capitalization 10x Genomics Corp|TXG - Company Long-Term Liabilities|Company Current Liabilities 10x Genomics|Quick Liquidity Indicator 10xgenomics.com
- net income and valuation ratios data:
TXG - Profit After Payment of Taxes|Future Profit 10x Genomics, Inc.|TXG - Price to Earnings Multiple|Forward P/E Multiple 10xgenomics.com|TXG - Price to Net Income Growth Ratio|EV/EBITDA Multiple 10x|TXG - Operating profit before amortization|Earnings per share for the last twelve months 10x Genomics|TXG - Earnings per share for the last 12 months|Quarterly EPS earnings growth 10xgenomics.com|TXG - Earnings growth in current year|Earnings growth forecast for next year 10x Genomics, Inc.
- revenue and sales details:
General company analysis:10xgenomics.com, TXG
This indicator measures the consensus forecast for the growth rate of net earnings per share, reflecting market expectations regarding future business profitability. By analyzing the analyst EPS growth estimates chart on GURU.Markets, an investor can see the potential for 10x Genomics, Inc. (TXG) to monetize its monopoly position in spatial genomics through the expansion of Chromium and Xenium systems and steady revenue from the sale of consumables.
Analysis of competing companies
TEM (Tempus) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year QGEN (Qiagen)|Earnings growth forecast for next year IONS|RGEN (Repligen) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year aviditybiosciences.com RNA|CRISPR (CRSP) - Expected net earnings per share growth next year|genedx.com - Earnings growth forecast for next year|Expected earnings per share trend next year RARE (ultragenyx.com)|BEAM: Earnings growth forecast for next year|Sarepta - Expected earnings per share trend next year|TWST (twistbioscience.com) - Earnings growth forecast for next year|NTLA: Expected earnings per share trend next year|Expected earnings per share growth for next year STOK (Stoke Corp)|Consensus forecast of earnings per share growth for next year biolifesolutions.com|Earnings growth forecast for next year WVE (Wave Life Sciences Ltd)|Consensus forecast of earnings per share growth for next year Maze Therapeutics (MAZE)|SION: Expected earnings per share growth for next year|Consensus forecast of earnings per share growth for next year Prime Medicine Bio PRME|TSHA: Earnings growth forecast for next year|Projected earnings per share growth rate for next year QURE|Expected earnings per share growth for next year MGTX|Projected earnings per share growth rate for next year RGNX (REGENXBIO)|Earnings growth forecast for next year SLDB|OCGN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Pacific Biosciences of California PACB|BNTC: Projected earnings per share growth rate for next year|DSGN - Net earnings per share growth forecast for next year|RCKT: Net earnings per share growth forecast for next year|FDMT - Projected earnings per share increase next year|Expected net earnings per share growth next year Lexeo Therapeutics Inc. (LXEO)|Net earnings per share growth forecast for next year Korro Bio Inc.|Editas Medicine (EDIT) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Silence Therapeutics Inc. (SLN)|PRQR: Net earnings per share change forecast for next year|Earnings growth forecast for next year CDXS (codexis.com)|SGMO: Projected earnings per share growth rate for next year|NAUT: Expected earnings per share growth for next year|Expected net earnings per share growth next year metagenomi.co|Precision BioSciences, Inc. (DTIL) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Generation Bio Corp (GBIO)|Expected earnings per share growth for next year BOLD|exicuretx.com (XCUR) - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year IMNN (Celsion Corporation)|PHIO (Phio Pharmaceuticals Corp.) - Expected earnings per share trend next year|Earnings growth forecast for next year MBIO (Mustang Bio Corp)|Projected earnings per share increase next year RNAZ (TransCode Therapeutics)|BNGO - Net earnings per share growth forecast for next year|APDN: Net earnings per share growth forecast for next year|BLUE: Earnings growth forecast for next year|Expected earnings per share growth for next year ImmunoPrecise Antibodies|OMGA (Omega Therapeutics, Inc.) - Earnings growth forecast for next year|Singular Genomics (OMIC) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Regulus (RGLS)|SYRS (Syros Pharmaceuticals, Inc) - Expected earnings per share trend next year|Telesis Bio, Inc. - Expected earnings per share growth for next year|TCON: Projected earnings per share growth rate for next year|Unity Biotechnology Inc. - Earnings growth forecast for next year
